Given the high frequency of FLT3 mutations and the development of resistance to drugs targeting them, there is a continuous interest in novel FLT3 inhibitors (Table 1 and Table 2 and Figure 2) to be used in combination therapies (e.g., through multi-targeted approaches), with the aim of eradicating leukemia while decreasing toxicity and enhancing treatment tolerability. The gene discussed is FLT3; the disease is leukemia.